

---

# Nutrizym<sup>®</sup>

---

## unique two-stage replacement or supplemental therapy in pancreatic insufficiency

*Extensive clinical evidence\* indicates that Nutrizym is significantly more effective than its competitors in improving fat absorption and protein digestion, and in reducing faecal weight.*

Each Nutrizym tablet has an enteric-coated pancreatic core and a shell of bromelains – proteolytic enzymes of the pineapple – which are active within the pH range of pH3 and pH8 (even pH2 for short periods) and therefore act without loss of enzymatic effectiveness at the low pH found in the stomach.

Following ingestion of the tablet, the bromelains are liberated in the stomach, where proteolytic action is required, and pancreatin is released in the duodenum. Additionally, the bromelains aid digestion in the small intestine where they develop their full proteolytic effect.

Nutrizym is indicated in: pancreatic deficiency states including post-gastrectomy malabsorption, fibrocystic and gastro-intestinal disorders resulting in steatorrhea.

Nutrizym: each tablet contains Bromelains 50mg. Pancreatin \*\* 4 x N.F. 400mg, and Ox bile 30mg.

\*\* activity equivalent to four times pancreatin B.P.

Dosage: 1 tablet to be taken with meals. Further tablets may be taken according to the degree of pancreatic exocrine insufficiency.

Full information on request


---

## **E. Merck Limited, Wokingham, Berks.**

---

\*Brit.med.J., 1970, 4, 21    Medical Digest, 1972, 17, 54    Gastroenterologie 1969, 7, 314.

---



# ACM Gastro-Duodenoscope FO-5008

**A side viewing Fiberscope for Gastro-Duodenal examination, Biopsy (7FG.), and Cannulation**

## TECHNICAL SPECIFICATIONS

Working Length : 120 cm

Tip Deflection : 110° Polydirectional

Diameter : 12.7 mm

Biopsy : 7 FG Martin Type Forceps Deflectable to 90°

Optical Field : 70° Fixed Focus

Photography : Current Techniques Applicable

Robust Construction with Precise Control




**THE MEDICAL SUPPLY ASSOCIATION LIMITED**

KINGS CROSS ROAD, DUNDEE, DD2 3QE


TELEPHONE 0382 88241

# GASTRIC REFLUX



## causes heartburn


Reflux of gastric acid, which inflames and eventually erodes the delicate oesophageal mucosa, frequently gives rise to burning chest pain—described by the patient as 'heartburn'—a symptom which heralds more serious trouble unless it is dealt with promptly and thoroughly.



**Heartburn in:**  
 Gastric reflux  
 Reflux oesophagitis  
 Hiatus hernia  
 Pregnancy



# GAVISCON REFLUX



## prevents heartburn

1 By forming a viscous demulcent gel which floats as a 'raft' over the stomach contents Gaviscon physically suppresses gastric reflux.

2 When reflux becomes particularly vigorous the Gaviscon 'raft' itself is the first fraction to enter the oesophagus where it presents a unique physical barrier to acid attack—even when the patient stoops or lies down.

3 By thus soothing and protecting the delicate mucosa Gaviscon prevents pain, permits regression of inflammation and allows the irritated cardiac 'sphincter' to resume its normal competence.

4 A double-blind trial in patients with sliding hiatus hernia showed that Gaviscon produced almost total relief of regurgitation and heartburn in 79% and 67% of the patients respectively.\*


# GAVISCON<sup>Regd</sup>

## GASTRIC REFLUX SUPPRESSANT

Gaviscon contains: Alginate Acid BPC, Sodium Alginate BPC, Magnesium Trisilicate BP, Dried Aluminium Hydroxide Gel BP, Sodium Bicarbonate BP, Sucrose BP and Mannitol BP. Gaviscon is available as mint flavoured tablets and chocolate flavoured granules.

\* *Current Medical Research and Opinion*, (1972) 1, 63.

inside  
every Baritop can  
are fine radiographs  
waiting  
to get out



The excellent fluidity and optimum concentration of Baritop 100 form a unique combination of properties which results in superior visualisation of mucosal detail. Carbon dioxide is incorporated as an effervescent agent to aid double-contrast procedures and enhance the exceptional palatability of the suspension.

Baritop 100 is the modern liquid barium specifically formulated to match the sophistication of present day equipment and techniques.

The elegant barium suspension at 100% w/v in convenient 300ml cans.

**Low viscosity**  
**High density**  
**Carbonated**  
**barium**  
**Baritop 100**


**world's finest micronised  
barium suspension**  
**from Japan**

For more information available  
write to

Concept Pharmaceuticals Limited  
Rickmansworth WD3 1EZ

Baritop is a registered trade mark.

she gets them  
to school  
late...




because of  
persistent  
diarrhoea

Persistent diarrhoea is one of the commonest presenting symptoms of irritable colon—and it is quickly and easily controlled by Colofac. Colofac reduces colonic hyperactivity by a direct action exerted on the colon musculature. There are no atropine-like side effects or contra-indications. Colofac is supplied as tablets of 100 mg. mebeverine hydrochloride. Full information is available on request.

**duphar** DUPHAR LABORATORIES LIMITED WEST END SOUTHAMPTON TEL 04218 2281 

**colofac**<sup>®</sup>  
mebeverine

controls the colon  
controls the diarrhoea



## Flatulent dyspepsia. And the wind of change

The flatulent dyspeptic patient you see in hospital will most likely need both investigation and a change of treatment.

Maxolon offers a real change. For the persistent flatulent dyspeptic a change to Maxolon can mean a break in symptoms that have been recurring for months, even years. Within a week, Maxolon will prevent symptoms in 4 out of 5 patients. In a month normal motility may be re-

established—overcoming the underlying problem in many cases of digestive tract disorders.

*Full information on the uses of Maxolon in hospital is available on request.*

Maxolon\* (metoclopramide) is a product of



**Beecham Research  
Laboratories,**  
Brentford, England.

\*regd. 


**Maxolon** for flatulent dyspepsia

NEW ... for hospital use

the oral  
alternative to  
parenteral feeding

**The first oral diet that \***

\*



# CAVED-S TABLETS

## SOME TRIAL SUMMARIES

### GUT 1968-9 48-51

#### SUMMARY

In a double blind clinical trial in which 54 patients\* were included, the effect of deglycyrrhizinated liquorice was investigated. Duodenal ulcer cases showed marked symptomatic improvement, with radiological healing demonstrable in a few cases.

\*48 Duodenal ulcer patients: 6 gastric ulcer patients.

Further confirmation of the activity of the drug was obtained from the treatment of six cases of gastric ulcer all of which showed extensive healing. Radiology demonstrated that the effect of the drug was spasmolytic in all duodenal ulcer patients, and that the side-effects were minimal. The great advantage of the treatment is that patients can be treated as ambulant and with a minimum loss of work.

### GUT 1971-72 449-451

#### SUMMARY

In our study no significant differences were found between the placebo and the treated groups.

The differences between the reported results are not easy to explain. Crossover trials in patients with duodenal ulcer are not easy to evaluate. In particular, it is not clear how after one month of reportedly successful therapy with complete relief of symptoms another drug (placebo) can be evaluated using clinical criteria. Even if the placebo is used first, the attack may be expected to subside within a month in part of the group.

In view of the conflicting reports more studies will have to be performed before a therapeutic effect can be attributed to deglycyrrhizinated liquorice in patients with duodenal ulcer.

It is not clear whether our results reflect on the efficacy of liquorice extract after the removal of carbenoxolone or merely on its efficacy in duodenal as contrasted to gastric ulcer. In common with others we found no side effects attributable to treatment with deglycyrrhizinated liquorice.

### GUT 10 299-302 1969

#### SUMMARY

In a double-blind clinical trial of deglycyrrhizinated liquorice 16 patients with gastric ulcer received the active drug for four weeks in a dose of 760 mg thrice daily and 17 the placebo. All patients, except four from each group who remained ambulant, were treated as outpatients. The results of the trial were assessed by the change in the size of the ulcer crater on barium meal before and after treatment.

Of the patients given the active drug, on average the size of the ulcer niche was reduced by 78%; in six patients (44%) the crater disappeared radiologically. In contrast the average reduction in size of the ulcer niche of the placebo group was 34% and in only one (6%) did the ulcer disappear. The difference in the reduction in ulcer size in favour of the treated group compared with the control group is statistically significant ( $P < 0.001$ ). None of the patients developed oedema and there was no excessive weight gain.

A pilot trial using Caved-(S) in a dose containing 760 mg of deglycyrrhizinated liquorice thrice daily for one month showed no toxic effects on fluid and electrolyte balance in 10 patients.


Protective Action of Deglycyrrhizinated Liquorice on the Occurrence of Stomach Ulcers in Pylorus-Ligated Rats. *Scand. J. Gastroent.*, 6, 683-686.

The effect of graded doses of a deglycyrrhizinated liquorice extract (d.Li.) was studied on the frequency of stomach ulcers and the secretion of gastric juice in pylorus-ligated rats. 25-50 mg of d.Li. given intraperitoneally reduced considerably the number of ulcers in comparison with the control group of rats without any significant changes in gastric secretion. Higher doses—100-200 mg—gave complete protection against the development of gastric ulcers and also reduced the output of gastric juice. The results give strong support for the existence of an ulcer-protecting principle in the d.Li.

*Key-words:* Gastric secretion; gastric ulcers; liquorice; pylorus-ligated rats.

*Dept. of Pharmacology, Karolinska institutet, S-104 01 Stockholm 60, Sweden.*





## Where does an endoscopist look for all round service?

To KeyMed! The Company that boasts the most comprehensive fund of expertise in fiberoptic endoscopy.

To KeyMed! Selling and servicing Olympus instruments. Olympus, world leaders in fiberoptic endoscopes—cover more specialities than any other with the finest instruments.

KeyMed, the first Company with a comprehensive repair service by specially trained technicians, in new laboratories. KeyMed – the Company that takes the trouble to know what's going on in fiberoptic endoscopy around the world. And backs up its experience and knowledge with service second to none.

# KEY MED

the specialist service for endoscopy equipment

KEY MED  
specialised medical  
equipment limited

KeyMed House Stock Road  
Southend on Sea SS2 5QH  
Further information can be simply  
obtained by using the KEYMED Free  
Post Information Service,  
addressing envelope  
without postage to: KeyMed  
Free Post Southend-on-Sea SS2 4BR



# There's only one healing agent for peptic ulcers as well documented as Biogastrone



## and that's Duogastrone

Carbenoxolone is the most thoroughly investigated healing agent available today—and interesting evidence is still mounting. For instance, a recent report\* suggests very strongly that carbenoxolone's proven healing properties are not only due to an increase in protective mucus or the creation of a more favourable healing environment – but also to more radical influences. These investigations appear to demonstrate that carbenoxolone actually prolongs the life-span of mucosal epithelial cells and reduces the rate of cell turnover.

Fascinating findings which shed new light on the disease process and provoke re-appraisal of current therapies. \*Gut, 1971, 12, 599-603

### **BIOGASTRONE®**

Carbenoxolone sodium tablets for gastric ulcer.

### **DUOGASTRONE®**

Carbenoxolone sodium capsules for duodenal ulcer.



Berk Pharmaceuticals Limited  
Godalming & Shalford, Surrey.



The Queen's Award to Industry 1972 to Biorex Laboratories Limited for Technological Innovation in the Development and Production of the drug Carbenoxolone Sodium for the treatment of ulcers.

Made under licence from Biorex Laboratories London  
British Patent numbers 843133, 1093286.

•Registered trade mark

J4273

# duphalac<sup>®</sup> in lactulose liver failure

*Duphalac (lactulose) is now well established as a valuable agent in the treatment of portal-systemic encephalopathy. A recent review in Gut\* describes its role in these terms.*

"Lactulose is a useful addition to the existing treatment of cirrhotic patients with neuropsychiatric disorders. Most patients respond particularly those with mild and relatively stable symptoms; such patients may receive lactulose indefinitely, and enjoy improved tolerance of dietary protein . . .  
. . . lactulose is free from significant side effects, and therefore falls into place as a valuable alternative to antibiotics when prolonged therapy is required". \*Gut, 1970, 11 : 1043-1048

***The following work on Duphalac in portal systemic encephalopathy has been published:***

Treatment of chronic portal-systemic encephalopathy with lactulose *Lancet*, 1966, 1 : 890-892

Portal-systemic encephalopathy treated with lactulose (letter) *Lancet*, 1966, 2 : 281

Treatment of hepatic system encephalopathy with lactulose *Medical Journal of Australia*, 1968, 2 : 160-163

Treatment of portacaval encephalopathy by lactulose *Presse medicale*, 1968, 76 : 1675-1676

Cirrhosis, hyperammonaemia and lactulose *Tijdschrift voor Gastro-Enterologie*, 1968, 11 : 123-139

Lactulose in the treatment of chronic portal-systemic encephalopathy: a double-blind clinical trial *New England Journal of Medicine*, 1969, 281 : 408-412

Long-term treatment of portal-systemic encephalopathy with lactulose *Australasian Annals of Medicine*, 1969, 18 : 117-123

Die Behandlungen des chronischen Coma hepaticum mit Laktulose *Therapeutische Umschau und medizinische Bibliographie*, 1969, 26 : 275-277

Lactulose treatment of chronic hepatoportal encephalopathy: a clinical and electroencephalographic study *Acta medica Scandinavica*, 1970, 187 : 337-346

The value of EEG frequency analysis in hepatic encephalopathy *J. Ryl. Coll. Surg. Edinb.*, 1970, 15 : 151-157

Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy *Quarterly Journal of Medicine*, 1970, 39 : 245-263

A controlled clinical trial of lactulose in hepatic encephalopathy *Gastroenterology*, 1970, 59 : 827-832

**Duphalac syrup is supplied in bottles of 200 ml and 2 litres. It contains lactulose 50% w/w, galactose 8% w/w and lactose 5% w/w.**

Further information available on request.

# ARCHIVES FRANÇAISES DES MALADIES DE L'APPAREIL DIGESTIF



**The most important French periodical on the subject**

*Organe Officiel de la Société Nationale Française de Gastro-Entérologie et de ses filiales*

Publishing all articles concerning the work of physicians, surgeons, electro-radiologists and biologists which are relevant to Gastro-enterology.

Starting in 1968, the "Archives Françaises des maladies de l'appareil digestif" — publish four numbers a year entitled "Biologie et Gastroentérologie" devoted to reports on experimental work in gastro-enterology carried out in the new research units of the various French University Hospital Centres.

These articles are original works, clinical, radiological, biological and anatomy-pathological papers (with illustrations and bibliography). The articles are written in French and followed by a summary in French and English. The Archives also publish summaries of the Proceedings of the Societies of which they are the

official organ, the texts of conferences or communications which are presented to them, Proceedings of Congresses or Colloquia, book and journal reviews.

The Archives publish announcements of national and international meetings on all subjects concerned with Gastro-enterology.

## SOME ARTICLES RECENTLY PUBLISHED

**Superficial cancers of the stomach. 41 cases**, by MM. J. MOREAUX, E. MARTIN, J. MOMBET, P. HOUSSET and P. BLOCH

**Radioimmunoassay of circulating carcino-embryonic antigen. Immuno-perchloric extraction of serum**, by MM. F. MARTIN, C. KLEPPING and J. GUERRIN

**Controlled study of maintenance treatment between acute attacks of duodenal ulcer**, by MM. H. SARLES, R. CAMATTE, A.-P. GAUTHIER and M. BOUILLON

**Blood-pressure and peptic ulcer**, by MM. G. GOULIS, D. SAKELLARIDIS, E. SIDIROPOULOS and L. CONCOURIS

**Submucous lipoma of the colon. A review of 7 cases**, by MM. F. OTTENI, A. KLEIN, G. STOLL and L.-F. HOLLENDER

**Zollinger-Ellison syndrome with carcinoid-islet cell tumor of the gall-bladder**, by MM. P. BERNADES, A. BONNEFOND, E. MARTIN and S. BONFILS

**Non-cirrhotic subacute fatal cholestatic hepatitis**, by MM. A. VACHON, J. BARTHE, R. TÊTE, P. PALIARD, M. PIANTE and J.-A. CHAYVIALLE

**Functional renal inadequacy in cirrhotics. Development. Mechanism. Treatment**, by P. VESIN

**Digestive mucous secretions**, by R. LAMBERT

**Hemobilia**, by H. BISMUTH

**Isolated organs perfusion: pancreas**, by J. P. PASCAL

**Isolated organs perfusion: stomach and small intestine**, by V. VARRO

*Subscription (12 numbers) 1972. France F.175. Other countries F.235.*

*Specimen copy available on application to:*

**MASSON & CIE** — Editeurs. 120 Boulevard Saint Germain, **75280 Paris Cedex 06**

# The single solution

for parenteral nutrition


## Aminoplex 5

1 litre three times per day provides 15g. of utilisable nitrogen and 3000K calories; the nutrient content being derived from synthetic L-Form amino acids, sorbitol and alcohol.

### Geistlich Chester

*In co-operation with Salvia-Werk  
G.m.b.H., Homburg/Saar, W.Germany.*

Medical literature  
available from:  
**Geistlich Sons Ltd.,**  
Newton Bank,  
Long Lane,  
Chester CH2 3QZ.  
Telephone  
Chester 47534-7





# Digestion

Contents  
Vol. 7,  
No. 3-4,  
1972

|   |     |
|---|-----|
| <i>Khodadoost, J. and Glass, G.B.J.</i> (New York, N.Y.): Erosive Gastritis and Acute Gastroduodenal Ulcerations as Source of Upper Gastrointestinal Bleeding in Liver Cirrhosis .....  | 129 |
| <i>Bloch, R.; Menge, H.; Martini, G.A., and Riecken, E.O.</i> (Marburg/Lahn): Effect of Gluten on Glucose Absorption from the Small Intestine in Experimentally Induced Malabsorption in Rats .....                             | 139 |
| <i>Gilat, T.; Fischel, B.; Danon, J., and Loewenthal, M.</i> (Tel Aviv): Morphology of Small Bowel Mucosa in Malignancy .....   | 147 |
| <i>Hirsch-Marie, H. and Huguet, C.</i> (Paris): Quantitative Determination of the Alphafetoprotein (AFP) .....  | 156 |
| <i>Madeira, F.; Quina, M., and Sanguino, J.C.</i> (Lisbon): Quantitative Hepatic Cytology. Experimental Study .....   | 165 |
| <i>Simon, L. and Figus, A.I.</i> (Jászberény): Diagnostic Value of Determination of Lactate Dehydrogenase and $\beta$ -Glucuronidase Activity of Gastric Juice. Correlation with a Histologic Study of the Gastric Mucosa ..... | 174 |
| <i>Ramboer, C.; Piessens, F., and Groot, J. de</i> (Leuven): Serum Xanthine Oxidase and Liver Disease .....   | 183 |
| <i>Sarles, J.C.; Varette, I., and Hage, G.</i> (Marseille): The Role of Lymphatic Obstruction and Partial Occlusion of the Suprahepatic Vein in the Pathogenesis of Chronic Perihepatitis (Perihepatitis encapsulans) .....     | 196 |
| <i>Jordö, L. and Olsson, R.</i> (Göteborg): The Effect of Long-Term Heparin Administration on Experimental Liver Fibrosis in Rats .....   | 204 |
| <i>Kowalewski, K.</i> (Edmonton, Alberta): Gastric Secretion and Peptic Ulcer in Rats with Experimentally-Induced Polycythemia .....  | 212 |
| <i>Parkash, O.</i> (Vienna): A Statistical and Clinical Evaluation of the Efficacy of the Enzyme Inhibitor Trasylol in the Treatment of Acute Forms of Pancreatitis .....   | 220 |
| <i>Desai, H.G.; Zaveri, M.P., and Antia, F.P.</i> (Bombay): Comparison of Dose-Response Curves with Subcutaneous Histamine and Penta-gastrin. Variations of Acid Secretion in Relation with Time .....                          | 227 |
| Case Report   |     |
| <i>Mainquet, P.; Thys, O.; Paulet, P., and Kiekens, R.</i> (Brussels): A Syndrome of Polyvalent Deficiencies after Gastrectomy .....  | 232 |
| General Review  |     |
| <i>Chey, W.Y.</i> (Rochester, N.Y.): Alcohol and Gastric Mucosa .....   | 239 |
| Book Reviews .....  | 252 |

Ask for  
specimen copies

All orders from the U.K. to be placed with  
J. Wiley and Sons Ltd., Baffins Lane, Chichester, Sussex

S. Karger Basel (Switzerland) New York